Claritev Forms Strategic Relationship with Kinetiq Health
Claritev announced a strategic relationship with Kinetiq Health. The combined offering delivers monthly medical and pharmacy claims surveillance, risk stratification, and intervention support from clinical and financial experts. Clients also gain access to Kinetiq Health's Second Opinion Program.
Trade with 70% Backtested Accuracy
Analyst Views on CTEV
About CTEV
About the author
Claritev to Present at 2026 J.P. Morgan Healthcare Conference, Enhancing Healthcare Affordability
- Conference Participation: Claritev Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, showcasing its innovations in healthcare technology, which is expected to attract investor attention and enhance the company's visibility.
- Technological Edge: As a company focused on healthcare affordability and transparency, Claritev leverages over 40 years of claims repricing experience and AI technology to provide data-driven solutions aimed at optimizing healthcare networks and benefits design.
- Market Coverage: Claritev serves over 700 healthcare payors, more than 100,000 employers, 60 million consumers, and 1.4 million contracted providers, demonstrating its extensive influence and market penetration within the healthcare industry.
- Strategic Goals: By offering purpose-built solutions, Claritev aims to support all key stakeholders, including payors, employers, and patients, thereby promoting accessibility and fairness in healthcare services, aligning with current trends in healthcare reform.
Claritev Shares Drop 20% Following Sale of 1.5 Million Shares by Stockholders
Stock Price Decline: Claritev Corporation (CTEV) experienced a significant drop of 20.5%, closing at $46.6, following the announcement of a public offering of 1,500,000 shares of Class A common stock by existing stockholders.
Underwriter Options: The underwriters were granted a 30-day option to purchase an additional 225,000 shares, but Claritev will not receive any proceeds from this offering as all shares are sold by current holders.
Market Reaction: The market reacted negatively to the increased float and selling pressure, with CTEV's trading volume surging above normal levels as investors processed the offering details.
Stock Performance: On the day of the announcement, CTEV opened at $57.98, reached a high of $58.10, and a low of $46.25, with a previous close of $58.62, and its 52-week trading range is noted to be $41.70 - $68.90.
